Jonathan Palmer

And how do you, I guess, maybe cut through some of the hype that we see in the marketplace?

That all makes sense.

I'd be curious to know, do you have a view in terms of how AI might speed up clinical trials?

And this is, I guess, maybe one of the

areas of debates that we have with a lot of our clients is, you know, can we speed up trials from, I don't know, seven years to five years, five years to four years?

You know, what's your view on the ability of AI to really improve the timelines for clinical trials?

Great to hear.

So when I think about the industry at large and some of the challenges that I think pharma has faced over the last couple of years, the uncertainty coming out of Washington, you know, whether it's on the regulatory front or executive orders, these sorts of things.

How do you think about where to push your chips in through that lens of some of this uncertainty that's coming around, whether it's most favored nations pricing, tariffs, these sorts of things?

I mean, does that factor into your investment process at all?

on us and where we're investing.

No, that makes sense.

I was curious at a high level if that impacted you guys at all.

As we think about the next, I don't know, maybe five to 10 years, whatever timeframe you think is appropriate, what technologies, I mean, we've talked a lot about the AI piece, but what are you really excited about that's emerging in your four quadrants that's really going to change the world for your pharma base over the next long-term horizon?

Well said.

It's great that you brought up Glenn a couple of times because we're hosting him again in a couple of weeks here.

His episode is going to follow yours not long afterwards.

So this is a good preview on what's going on at Transparent.

One of the things you touched on in that last discussion was the global access.

And I guess maybe through the lens of international, how are you thinking about the international opportunities?